First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial

被引：98

作者：

Costa, Luciano J. ^{[1
]}

Wong, Sandy W. ^{[2
]}

Bermudez, Arancha ^{[3
]}

de la Rubia, Javier ^{[4
]}

Mateos, Maria-Victoria ^{[5
]}

Ocio, Enrique M. ^{[3
]}

Rodriguez-Otero, Paula ^{[6
]}

San-Miguel, Jesus ^{[6
]}

Li, Shaoyi ^{[7
]}

Sarmiento, Rafael ^{[8
]}

Lardelli, Pilar ^{[8
]}

Gaudy, Allison ^{[7
]}

Boss, Isaac ^{[9
]}

Kelly, Lisa M. ^{[10
]}

Burgess, Michael R. ^{[10
]}

Hege, Kristen ^{[10
]}

Bensinger, William I. ^{[11
]}

机构：

[1] Univ Alabama Birmingham, Div Hematol & Oncol, Birmingham, AL USA

[2] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA

[3] Hosp Univ Marques de Valdecilla IDIVAL, Santander, Spain

[4] Univ Hosp Doctor Preset, Hematol Serv, Valencia, Spain

[5] Univ Hosp Salamanca, Inst Canc Mol & Cellular Biol, Salamanca, Spain

[6] Univ Navarra Clin, Dept Hematol, CIMA, Pamplona, Spain

[7] Celgene Corp, Summit, NJ USA

[8] Celgene Inst Translat Res Europe, Seville, Spain

[9] Celgene Corp, Seattle, WA USA

[10] Celgene Corp, San Francisco, CA USA

[11] Swedish Canc Inst, Myeloma & Transplant Program, Seattle, WA USA

来源：

关键词：

D O I：

10.1182/blood-2019-122895

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

143

引用

页数：5